Mitoxantrone interactions

When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)] . (Fingolimod label, Drug interactions)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (Sofosbuvir and velpatasvir label, Drug interactions)

Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (Cyclosporine label, Drug interactions)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (Mitoxantrone label, Warnings)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (Mitoxantrone label, Warnings)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (Eltrombopag label, Drug interactions)

Among 112 patients evaluable for safety on the mitoxantrone injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. (Mitoxantrone label, Warnings)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (Leflunomide label, Drug interactions)

When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ]. (Ocrelizumab label, Drug interactions)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (Mitoxantrone label, Warnings)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (Teriflunomide label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

In first-line comparative trials of mitoxantrone injection + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. (Mitoxantrone label, Warnings)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

• Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). (Natalizumab label, Warnings and precautions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Mitoxantrone label, Drug interactions)